Efficient therapy of ischaemic lesions with VEGF121-fibrin in an animal model of systemic sclerosis

about

Efficient therapy of ischaemic lesions with VEGF121-fibrin in an animal model of systemic sclerosis

Item

http://www.wikidata.org/entity/Q38625028

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Efficient therapy of ischaemic ...... al model of systemic sclerosis

@en

type

Item

label

Efficient therapy of ischaemic ...... al model of systemic sclerosis

@en

prefLabel

Efficient therapy of ischaemic ...... al model of systemic sclerosis

@en

P1476

Efficient therapy of ischaemic ...... al model of systemic sclerosis

@en

P2093

Hermann Dietrich

http://www.w3.org/2001/XMLSchema#string

Ines Wasle

http://www.w3.org/2001/XMLSchema#string

Johann Gruber

http://www.w3.org/2001/XMLSchema#string

Marion Mailänder

http://www.w3.org/2001/XMLSchema#string

Oliver Distler

http://www.w3.org/2001/XMLSchema#string

Roswitha Sgonc

http://www.w3.org/2001/XMLSchema#string

Shadab Allipour Birgani

http://www.w3.org/2001/XMLSchema#string

P2860

Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers

Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice

Molecular mechanisms and clinical applications of angiogenesis

Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization.

Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis.

The vascular perspective of systemic sclerosis: of chickens, mice and men.

Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy.

The pathogenesis of systemic sclerosis.

Angiogenic cytokines and growth factors in systemic sclerosis.

Adjusting for multiple testing--when and how?

P304

1399-1406

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2015-207548

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26362758

http://www.w3.org/2001/XMLSchema#string

P932

4766736

http://www.w3.org/2001/XMLSchema#string